$39.45
1.42%
Nasdaq, Nov 18, 04:00 pm EST. Closed.
ISIN
US81734D1046
Symbol
SEPN

Septerna Stock price

$39.45
+3.07 8.44% 1M
+13.15 50.00% 6M
+11.57 41.50% YTD
+17.76 81.88% 1Y
+21.45 119.17% 3Y
+21.45 119.17% 5Y
+21.45 119.17% 10Y
+21.45 119.17% 20Y
Nasdaq, Closing price Wed, Nov 18 2026
-0.57 1.42%
ISIN
US81734D1046
Symbol
SEPN
Industry

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$1.5b
Net debt
positive
Cash
$372.3m
Shares outstanding
45.7m
Valuation
P/E
negative
P/S | estimate
19.0 | 18.8
EV/Sales | estimate
15.2 | 15.0
EV/FCF | ex SBC
14.3 | 16.9
P/B
4.9
Financial Health
Equity Ratio
64.1%
Return on Equity
-12.8%
ROCE
-8.9%
ROIC
-35.7%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$16.3m | 16.5%
SBC as % of FCF
15.5%
SBC Growth 1Y
211.3%
Share Count Growth 1Y
2.5%
Shareholder Yield
-2.5%
Financials
Revenue | estimate
$98.9m | $100.0m
EBITDA
$-41.9m
EBIT
$-43.5m
Net Income
$-24.2m
Free Cash Flow | ex SBC
$105.1m | $88.8m
Growth
Revenue | estimate
13,445.2% | 117.5%
EBITDA
58.3%
EBIT
57.4%
Net Income
72.3%
Free Cash Flow
226.6%
Margin
Gross
-
EBITDA
-42.4%
EBIT
-44.0%
Net
-24.5%
Free Cash Flow | ex SBC
106.3% | 89.8%
More
EPS
$-0.5
FCF per Share
$2.3
Short interest
13.3%
Employees
130
Rev per Employee
$350.0k

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Septerna forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Septerna forecast:

Buy
94%
Hold
6%

Septerna Events

Past Events
NOV
16
UBS Global Biopharma Conference 2026
3 days ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago

Financial data from Septerna

Jun '26
+/-
%
99 99
13,445% 13,445%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
41% 41%
35%
- Research and Development Expense 121 121
54% 54%
122%
-42 -42
58% 58%
-42%
- Depreciation and Amortization 1.65 1.65
6% 6%
2%
EBIT (Operating Income) EBIT -44 -44
57% 57%
-44%
Net Profit -24 -24
72% 72%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Neutral
GlobeNewsWire
●
10 days ago
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash Position of $565.2 Million Expected to Support Operating Plans at Least into mid-2029 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a cli...
Neutral
GlobeNewsWire
●
15 days ago
Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial initiation planned for the first quarter of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company...
Neutral
GlobeNewsWire
●
2 months ago
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company's common stock to Rajiv Patni, M.D., the Company's newly appointed Chief Medical Officer, under the Company's 2026 Inducement Plan (the “Inducement Plan”). The inducement grant was eff...
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dr. Finer
Employees 130
Website www.septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today